Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CriTiClean

Financiado

Cerrado

Supercritical carbon dioxide for delipidation of soft tissue Suppressing trans...

Supercritical carbon dioxide for delipidation of soft tissue Suppressing transplant rejection. The lack of donor organs and tissue constitutes a health and social problem. In 2014 about 119.873 organs were transplanted, that is less than the 10% of global needs. Critical patients do not survive the waiting time while transp... ver más

13/07/2019

LUNDS UNIVERSITET

174K€

Presupuesto del proyecto: 174K€

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-07-13

MSCA-IF-2016: Individual Fellowships

I+D

Cerrada hace 8 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

LUNDS UNIVERSITET

173.86K€ | Lider

Proyectos interesantes

PRE2018-085772

Medical Technol...

Chemical Engine...

93K€ Cerrado

SAF2015-64224-R

Medical Technol...

Transplantation

121K€ Cerrado

PRESERVE

Medical Technol...

Biotechnology

Cerrado

Rethyming

Medical Technol...

Biotechnology

1M€ Cerrado

exTra

Medical Technol...

Medical Devices

Cerrado

PhotoPHARMA

Medical Technol...

Chemical Engine...

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 28 meses Fecha Inicio: 2017-03-07
Fecha Fin: 2019-07-13

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 174K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The lack of donor organs and tissue constitutes a health and social problem. In 2014 about 119.873 organs were transplanted, that is less than the 10% of global needs. Critical patients do not survive the waiting time while transplanted people must receive lifelong immunosuppressive therapy with severe side effects. Also, there is a risk to lose the new organ to chronic rejection, which is linked to the presence of cellular components e.g. glycolipids and lipoproteins in the donor tissue. There is currently no process to remove lipids and lipid antigens from soft tissue prior transplantation. Supercritical carbon dioxide (scCO2) is known to extract lipids from solid matrices, while polar molecules of high molecular weight, such as structural proteins in soft tissue, are insoluble. In this project we will explore the use of scCO2 to remove lipid compounds from soft tissue (i.e. pulmonary arteries) as a novel process for tissue preparation in order to suppress the main cause of rejection associated with transplantation. Fundamental studies on solubility of lipids in scCO2-water-ethanol mixtures are necessary to evaluate the extractability of lipids from fresh tissue, and will be performed by 'in-situ' Raman spectroscopy. Our approach avoids the use of current chemical and biological treatments that risk damaging the tissue and pose a toxic threat to the recipient organism. The mechanical properties of the cleaned tissue, the immunoresponse that provokes and its capacity for recellularization will be studied 'in vitro' and related to the amounts and type of remnant lipid compounds. The project brings supercritical fluid technology into the biomedical field. This work will lead to efficient methodologies to clean all kind of organs/soft tissue and will enable safe animal-to-human transplantation, a current dream that will increase the hope of critical patients and improve life-quality after transplantation by removing the need of immunosuppression.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores